MINYANVILLE ORIGINAL Since Amarin (NASDAQ:AMRN) won US approval for its fish-oil heart drug in late July there have been two topics of intense interest surrounding the company: Will it be taken over and will the new heart medicine Vascepa win a coveted protection for added market exclusivity? Investors are still waiting for answers. Amarin CEO Joseph Zakrzewski has said a takeover of the company is one of three paths for the company as it looks to launch Vascepa early next year. The drug is a pure fish-oil treatment -- more potent than over-the-counter products -- aimed at lowering triglycerides ...